XML 42 R32.htm IDEA: XBRL DOCUMENT v3.25.1
STOCK-BASED AND OTHER COMPENSATION (Tables)
3 Months Ended
Mar. 31, 2025
Share-Based Payment Arrangement [Abstract]  
Schedule of Restricted Common Stock Award
March 31, 2025December 31, 2024
Number of SharesWeighted
Average
Grant Price
Number of SharesWeighted
Average
Grant Price
Restricted Shares
Unvested and outstanding at beginning of year39,171 $12.48 75,601 $12.41 
Granted— — 16,955 11.88 
Vested(31,562)12.43 (53,139)12.19 
Forfeited— — (246)11.88 
Unvested and outstanding at end of period7,609 $12.68 39,171 $12.48 

March 31, 2025
Number of SharesWeighted
Average
Grant Price
Performance Based Restricted Shares
Unvested at beginning of year33,188 $13.09 
2022 performance shares awarded above target1,154 14.00 
Vested and issued 2022 performance shares(16,021)14.00 
Unvested at end of period18,321 $12.36 

December 31, 2024
Number of SharesWeighted
Average
Grant Price
Performance Based Restricted Shares
Unvested at beginning of year41,993 $12.61 
Granted— — 
Vested and issued(8,805)10.78 
Forfeited— — 
Unvested at end of period33,188 $13.09 
Schedule of Common Stock Option Awards
Option SharesWeighted
Average
Exercise
Price
Weighted
Average
Remaining
Contractual
Term in Years
Aggregate
Intrinsic
Value
March 31, 2025
Outstanding at beginning of year52,000 $11.62 
Exercised(3,000)9.20 
Outstanding at end of period49,000 $11.77 1.71$128 
Exercisable at end of period49,000 $11.77 1.71$128 
December 31, 2024
Outstanding at beginning of year54,000 $11.59 
Exercised(2,000)11.00 
Outstanding at end of year52,000 $11.62 1.85$243 
Exercisable at end of year52,000 $11.62 1.85$243 
Schedule of Information Related to Stock Option Plan
Information related to the 2008 Equity Incentive Plan for the respective periods follows:
Three months ended March 31, 2025Twelve months ended December 31, 2024
Intrinsic value of options exercised$19 $12 
Cash received from options exercised$28 $22 
Tax benefit realized from options exercised$— $—